Betahistine and combination products containing cinnarizine and dimenhydrinate in the treatment of vestibular vertigo Review article
Article Sidebar
Published:
Nov 30, 2023
Keywords:
vertigo, betahistine, cinnarizine, dimenhydrinate
Main Article Content
Abstract
Betahistine is widely used in the treatment of vestibular vertigo of various etiologies. Recently combination products containing cinnarizine and dimenhydrinate have also been used in the treatment of vestibular vertigo. They are not more effective than betahistine, and moreover, the short treatment period (up to 4 weeks) and side effects such as drowsiness and the effect on ability to drive and use machines limit their use. For this reason, these preparations can be used for a short time in the acute period of vestibulopathy, also in polypharmacotherapy with betahistine.
Article Details
How to Cite
Berkowicz , T. (2023). Betahistine and combination products containing cinnarizine and dimenhydrinate in the treatment of vestibular vertigo. Medycyna Faktow (J EBM), 16(3(60), 378-381. https://doi.org/10.24292/01.MF.0323.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Neuhauser HK. The epidemiology of dizziness and vertigo. Handb Clin Neurol. 2016; 137: 67-82. http://doi.org/10.1016/B978-0-444-63437-5.00005-4.
2. Corrales CE, Bhattacharyya N. Dizziness and death: An imbalance in mortality. Laryngoscope. 2016; 126(9): 2134-6. http://doi.org/10.1002/lary.25902.
3. Lea J, Pothier D (ed). Vestibular Disorders. Adv Otorhinolaryngol. Basel, Karger 2019; 82: 143-9.
4. Terroso M, Rosa N, Torres Marques A et al. Physical consequences of falls in the elderly: a literature review from 1995 to 2010. Eur Rev Aging Phys Act. 2014; 11: 51-9. http://doi.org/10.1007/s11556-013-0134-8.
5. Brandt T, Huppert T, Hüfner K et al. Long-term course and relapses of vestibular and balance disorders. Restor Neurol Neurosci. 2010; 28(1): 69-82. http://doi.org/10.3233/RNN-2010-0504.
6. Neuhauser HK, von Brevern M, Radtke A et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology. 2005; 65(6): 898-904. http://doi.org/10.1212/01.wnl.0000175987.59991.3d. Erratum in: Neurology. 2006; 67(8): 1528.
7. Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol. 2009; 29(5): 473-81. http://doi.org/10.1055/s-0029-1241043.
8. Odyniec A. Betahistine in treatment of vestibular vertigo – from molecular mechanism to clinical effect. Vertigoprofil. 2015; 7(2): 2-7.
9. Berkowicz T. Betahistine in the treatment of vertigo of different etiology. Neuropsychiatria. 2017; 9(3): 95-100.
10. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016; 2016(6): CD010696. http://doi.org/10.1002/14651858.CD010696.pub2.
11. Benecke H, Pérez-Garrigues H, Bin Sidek D et al.; OSVaLD investigators. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J. 2010; 16(1): 14-24.
12. Sienkiewicz-Jarosz H. Betahistyna w tabletkach ulegających rozpadowi w jamie ustnej w terapii pacjentów z zawrotami głowy. Vertigoprofil. 2016; 8(1): 14-7.
13. Maciejewska B. Wybrane aspekty farmakoterapii zawrotów głowy. Med Dypl. 2020; 29(9): 7381.
14. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Symtiver (access: 12.09.2023).
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Artigo (access: 12.09.2023).
16. Scholtz AW, Waldfahrer F, Hampel R et al. Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. Clin Drug Investig. 2022; 42(9): 705-20. http://doi.org/10.1007/s40261-022-01184-0.
17. Teggi R, Gatti O, Sykopetrites V et al. Association of cinnarizine and betahistine in prophylactic therapy for Ménière’s disease with and without migraine. Acta Otorhinolaryngol Ital. 2014; 34(5): 349-53.
18.Asadi P, Zia Ziabari SM, Majdi A et al. Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial. Eur J Clin Pharmacol. 2019; 75(11): 1513-9. http://doi.org/10.1007/s00228-019-02741-x.
2. Corrales CE, Bhattacharyya N. Dizziness and death: An imbalance in mortality. Laryngoscope. 2016; 126(9): 2134-6. http://doi.org/10.1002/lary.25902.
3. Lea J, Pothier D (ed). Vestibular Disorders. Adv Otorhinolaryngol. Basel, Karger 2019; 82: 143-9.
4. Terroso M, Rosa N, Torres Marques A et al. Physical consequences of falls in the elderly: a literature review from 1995 to 2010. Eur Rev Aging Phys Act. 2014; 11: 51-9. http://doi.org/10.1007/s11556-013-0134-8.
5. Brandt T, Huppert T, Hüfner K et al. Long-term course and relapses of vestibular and balance disorders. Restor Neurol Neurosci. 2010; 28(1): 69-82. http://doi.org/10.3233/RNN-2010-0504.
6. Neuhauser HK, von Brevern M, Radtke A et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology. 2005; 65(6): 898-904. http://doi.org/10.1212/01.wnl.0000175987.59991.3d. Erratum in: Neurology. 2006; 67(8): 1528.
7. Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol. 2009; 29(5): 473-81. http://doi.org/10.1055/s-0029-1241043.
8. Odyniec A. Betahistine in treatment of vestibular vertigo – from molecular mechanism to clinical effect. Vertigoprofil. 2015; 7(2): 2-7.
9. Berkowicz T. Betahistine in the treatment of vertigo of different etiology. Neuropsychiatria. 2017; 9(3): 95-100.
10. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016; 2016(6): CD010696. http://doi.org/10.1002/14651858.CD010696.pub2.
11. Benecke H, Pérez-Garrigues H, Bin Sidek D et al.; OSVaLD investigators. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J. 2010; 16(1): 14-24.
12. Sienkiewicz-Jarosz H. Betahistyna w tabletkach ulegających rozpadowi w jamie ustnej w terapii pacjentów z zawrotami głowy. Vertigoprofil. 2016; 8(1): 14-7.
13. Maciejewska B. Wybrane aspekty farmakoterapii zawrotów głowy. Med Dypl. 2020; 29(9): 7381.
14. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Symtiver (access: 12.09.2023).
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Artigo (access: 12.09.2023).
16. Scholtz AW, Waldfahrer F, Hampel R et al. Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. Clin Drug Investig. 2022; 42(9): 705-20. http://doi.org/10.1007/s40261-022-01184-0.
17. Teggi R, Gatti O, Sykopetrites V et al. Association of cinnarizine and betahistine in prophylactic therapy for Ménière’s disease with and without migraine. Acta Otorhinolaryngol Ital. 2014; 34(5): 349-53.
18.Asadi P, Zia Ziabari SM, Majdi A et al. Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial. Eur J Clin Pharmacol. 2019; 75(11): 1513-9. http://doi.org/10.1007/s00228-019-02741-x.